{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:59:00Z","timestamp":1783097940345,"version":"3.54.6"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"DOPPS Programs"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Optimal parathyroid hormone (PTH) control during non-dialysis chronic kidney disease (ND-CKD) might decrease the subsequent risk of parathyroid hyperplasia and uncontrolled secondary hyperparathyroidism (SHPT) on dialysis. However, the evidence for recommending PTH targets and therapeutic strategies is weak for ND-CKD. We evaluated the patient characteristics, treatment patterns and PTH control over the first year of haemodialysis (HD) by PTH prior to HD initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We studied 5683 incident HD patients from 21 countries in Dialysis Outcomes and Practice Patterns Study Phases 4\u20136 (2009\u201318). We stratified by PTH measured immediately prior to HD initiation and reported the monthly prescription prevalence of active vitamin D and calcimimetics over the first year of HD and risk of PTH &amp;gt;600\u2009pg\/mL after 9\u201312\u2009months on HD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The 16% of patients with PTH &amp;gt;600\u2009pg\/mL prior to HD initiation were more likely to be prescribed active vitamin D and calcimimetics during the first year of HD. The prevalence of PTH &amp;gt;600\u2009pg\/mL 9\u201312\u2009months after start of HD was greater for patients who initiated HD with PTH &amp;gt;600 (29%) versus 150\u2013300 (7%) pg\/mL (adjusted risk difference: 19%; 95% confidence interval : 15%, 23%). The patients with sustained PTH &amp;gt;600\u2009pg\/mL after 9\u201312\u2009months on HD were younger, more likely to be black, and had higher serum phosphorus and estimated glomerular filtration rates at HD initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Increased PTH before HD start predicted a higher PTH level 9\u201312\u2009months later, despite greater use of active vitamin D and calcimimetics. More targeted PTH control during ND-CKD may influence outcomes during HD, raising the need for PTH target guidelines in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa195","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T19:10:32Z","timestamp":1594321832000},"page":"160-169","source":"Crossref","is-referenced-by-count":35,"title":["The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation"],"prefix":"10.1093","volume":"36","author":[{"given":"Nahid","family":"Tabibzadeh","sequence":"first","affiliation":[{"name":"Renal Physiology Department, APHP H\u00f4pital Bichat, Universit\u00e9 de Paris, INSERM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Karaboyas","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M","family":"Robinson","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A","family":"Csomor","sequence":"additional","affiliation":[{"name":"Vifor Pharma Ltd, Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Clinical Development, Relypsa Inc., Vifor Pharma Group Company, Redwood City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-4321","authenticated-orcid":false,"given":"Pieter","family":"Evenepoel","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Microbiology and Immunology, Laboratory of Nephrology, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-1906","authenticated-orcid":false,"given":"Pablo-Antonio","family":"Ure\u00f1a-Torres","sequence":"additional","affiliation":[{"name":"Department of Dialysis, AURA Nord Saint Ouen, Saint-Ouen, France"},{"name":"Department of Renal Physiology, Necker Hospital, University of Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7832-2339","authenticated-orcid":false,"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology, and Metabolism, Tokai University School of Medicine, Isehara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa","family":"Al Salmi","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, Royal Hospital, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Pisoni","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W","family":"Young","sequence":"additional","affiliation":[{"name":"Arbor Research Collaborative for Health, Ann Arbor, MI, USA"},{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"2020122916300523800_gfaa195-B1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/ki.2009.189","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements","volume":"76","year":"2009","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020122916300523800_gfaa195-B3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","article-title":"Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients","volume":"67","author":"Nakanishi","year":"2005","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020122916300523800_gfaa195-B6","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2020122916300523800_gfaa195-B7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ajkd.2005.09.024","article-title":"PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis","volume":"47","author":"Danese","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.ki.5001542","article-title":"Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study","volume":"70","author":"Melamed","year":"2006","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2369-14-88","article-title":"Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis","volume":"14","author":"Natoli","year":"2013","journal-title":"BMC Nephrol"},{"key":"2020122916300523800_gfaa195-B10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","article-title":"Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study","volume":"26","author":"Naves-D\u00edaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2020122916300523800_gfaa195-B11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bone.2014.01.016","article-title":"Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients","volume":"61","author":"Streja","year":"2014","journal-title":"Bone"},{"key":"2020122916300523800_gfaa195-B12","doi-asserted-by":"crossref","first-page":"e0164865","DOI":"10.1371\/journal.pone.0164865","article-title":"Effects of secondary hyperparathyroidism treatment on improvement in anemia: results from the MBD-5D study","volume":"11","author":"Tanaka","year":"2016","journal-title":"PloS One"},{"key":"2020122916300523800_gfaa195-B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.ajkd.2008.11.029","article-title":"Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP)","volume":"53","author":"Bhuriya","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B15","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/ki.2008.64","article-title":"Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease","volume":"73","author":"Kovesdy","year":"2008","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/j.ajkd.2008.06.023","article-title":"Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort","volume":"52","author":"Levin","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B17","doi-asserted-by":"crossref","first-page":"c54","DOI":"10.1159\/000228076","article-title":"Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients","volume":"113","author":"Schumock","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"2020122916300523800_gfaa195-B18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1525-139X.2009.00581.x","article-title":"Parathyroid hormone, a uremic toxin","volume":"22","author":"Rodriguez","year":"2009","journal-title":"Semin Dial"},{"key":"2020122916300523800_gfaa195-B19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/ckj\/sfy061","article-title":"Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease","volume":"12","author":"Ure\u00f1a-Torres","year":"2019","journal-title":"Clin Kidney J"},{"key":"2020122916300523800_gfaa195-B21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.23876\/j.krcp.19.041","article-title":"Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease","volume":"38","author":"Abbas","year":"2019","journal-title":"Kidney Res Clin Pract"},{"key":"2020122916300523800_gfaa195-B22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40620-017-0397-7","article-title":"Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease","volume":"30","author":"Massy","year":"2017","journal-title":"J Nephrol"},{"key":"2020122916300523800_gfaa195-B24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1210\/endo.134.1.8275958","article-title":"Regulation of parathyroid hormone (PTH)\/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17\/2.8 and OK cells","volume":"134","author":"Ure\u00f1a","year":"1994","journal-title":"Endocrinology"},{"key":"2020122916300523800_gfaa195-B25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.kint.2015.12.001","article-title":"Low parathyroid hormone status induced by high dialysate calcium is an independent risk factor for cardiovascular death in hemodialysis patients","volume":"89","author":"Merle","year":"2016","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B26"},{"key":"2020122916300523800_gfaa195-B27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000188261","article-title":"Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients","volume":"68","author":"Fukagawa","year":"1994","journal-title":"Nephron"},{"key":"2020122916300523800_gfaa195-B28","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1172\/JCI117890","article-title":"Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia","volume":"95","author":"Arnold","year":"1995","journal-title":"J Clin Invest"},{"key":"2020122916300523800_gfaa195-B29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0272-6386(04)01099-6","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology","volume":"44","author":"Pisoni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B30","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1046\/j.1523-1755.2000.07413.x","article-title":"The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study","volume":"57","author":"Young","year":"2000","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B31"},{"key":"2020122916300523800_gfaa195-B32"},{"key":"2020122916300523800_gfaa195-B33","first-page":"303","article-title":"Pathophysiology of the Chronic Kidney Disease \u2013 Mineral Bone Disorder (CKD-MBD","volume":"24","author":"Hruska","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020122916300523800_gfaa195-B34","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1053\/ajkd.2001.27426","article-title":"Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases","volume":"38","author":"Fukagawa","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2020122916300523800_gfaa195-B35","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","article-title":"Parathyroid hormone metabolism and signaling in health and chronic kidney disease","volume":"90","author":"Evenepoel","year":"2016","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B37","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2020122916300523800_gfaa195-B38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO Randomized Controlled Trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"2020122916300523800_gfaa195-B39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2020122916300523800_gfaa195-B40","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jbmr.309","article-title":"Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients","volume":"26","author":"Malluche","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020122916300523800_gfaa195-B41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.1981.03310340020020","article-title":"Decreased secondary hyperparathyroidism in diabetic patients receiving hemodialysis","volume":"245","author":"Vincenti","year":"1981","journal-title":"JAMA"},{"key":"2020122916300523800_gfaa195-B42","doi-asserted-by":"crossref","first-page":"e0202417","DOI":"10.1371\/journal.pone.0202417","article-title":"Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care","volume":"13","author":"Borrelli","year":"2018","journal-title":"Plos One"},{"key":"2020122916300523800_gfaa195-B43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ckj\/sfz021","article-title":"Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study","volume":"12","author":"Rottembourg","year":"2019","journal-title":"Clin Kidney J"},{"key":"2020122916300523800_gfaa195-B44","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"2020122916300523800_gfaa195-B45","article-title":"One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism","author":"Bushinsky","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2020122916300523800_gfaa195-B46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"2020122916300523800_gfaa195-B47","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2013-1294","article-title":"Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold","volume":"98","author":"Metzger","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020122916300523800_gfaa195-B48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40620-015-0186-0","article-title":"Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low","volume":"29","author":"Ennis","year":"2016","journal-title":"J Nephrol"},{"key":"2020122916300523800_gfaa195-B49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"2020122916300523800_gfaa195-B50","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1306357","article-title":"Vitamin D-binding protein and vitamin D status of black Americans and white Americans","volume":"369","author":"Powe","year":"2013","journal-title":"N Engl J Med"},{"key":"2020122916300523800_gfaa195-B51","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfr535","article-title":"Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values","volume":"27","author":"Cavalier","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/1\/160\/35253583\/gfaa195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/1\/160\/35253583\/gfaa195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T21:30:41Z","timestamp":1609277441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/1\/160\/5929333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,17]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa195","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,10,17]]}}}